Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.
Level V
Where this comes from
- Record sourced from PubMed, PMID 27769809.
- Also identified by DOI 10.1053/j.gastro.2016.10.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication.
Medical subject headings
- Aminosalicylic Acids
- Anti-Bacterial Agents
- Biological Products
- Congenital Abnormalities
- Glucocorticoids
- Immunologic Factors
- Inflammatory Bowel Diseases
- Pregnancy Complications